

1 **Title:** Estimated Incidence of Respiratory Syncytial Virus (RSV)-related Hospitalizations for
2 Acute Respiratory Infections (ARIs), including Community Acquired Pneumonia (CAP), in Adults
3 in Germany

4 **Authors:** Caihua Liang¹, Elizabeth Begier², Stefan Hagel³, Juliane Ankert³, Liz Wang¹,
5 Claudia Schwarz⁴, Lea J. Bayer⁵, Christof von Eiff⁵, Qing Liu⁴, Jo Southern⁴, Jeffrey Vietri⁴,
6 Sonal Uppal⁴, Bradford D. Gessner⁴, Christian Theilacker⁴, Mathias Pletz³

7 **Affiliations:**

8 ¹Pfizer Inc-New York (USA)

9 ²Pfizer Inc-Dublin (Ireland)

10 ³ Institute for Infectious Diseases and Infection Control and Center for Sepsis Care and Control
11 (CSCC), Jena University Hospital, Friedrich- Schiller-University, Jena, Germany

12 ⁴Pfizer Inc-Collegeville (USA)

13 ⁵Pfizer Pharma GmbH, Berlin (Germany)

14 **Correspondence Details:**

15 Mathias W. Pletz (mathias.pletz@med.uni-jena.de)

16 **Abstract:**

17 **Background:** RSV is a leading cause of ARI, including CAP, in older adults, but available data
18 often substantially underestimate incidence. We estimated RSV-related ARI hospitalization
19 incidence from a prospective CAP study and adjusted for undiagnosed RSV infections due to
20 use of nasopharyngeal/nasal swab testing only.

21 **Methods:** We conducted active, population-based surveillance of adult CAP hospitalizations in
22 Thuringia (Germany) between 2021–2023. Participant nasopharyngeal/nasal swabs were RSV-
23 tested by multiplex nucleic acid amplification testing. To estimate RSV-related CAP incidence,
24 age-group specific proportions of RSV positivity among tested patients were applied to all-cause
25 CAP incidence. To adjust for underdiagnosis due to nasopharyngeal/nasal swab sampling only
26 and the percentage of ARI with pneumonia diagnoses, we used data from a large, prospective,
27 multispecimen study assessing impact of collecting multiple specimens (nasopharyngeal/nasal
28 swab, saliva, paired serology, and sputum) among 3,669 adults hospitalized for ARI.

29 **Results:** Among 1,040 enrolled adults (≥ 18 years) with radiologically confirmed CAP, 38 tested
30 RSV-positive via nasopharyngeal/nasal swab (3.7%). The percentage positive increased to
31 7.8% after adjusting for higher RSV detection with multiple specimens compared to
32 nasopharyngeal/nasal swab only. Adjusted RSV-related CAP hospitalization rates were 4.7
33 (95%CI 1.5–11.2) and 109.1 (95%CI 89.6–131.6) per 100,000 adults aged 18–59 and ≥ 60
34 years, respectively. Adjusted incidences of RSV-related ARI were 18.4 (95%CI 11.0–28.9) and
35 377.6 (95%CI 340.5–417.7) per 100,000 adults aged 18–59 and ≥ 60 years, respectively.

36 Among RSV-positive CAP hospitalizations, 12.1% of patients aged ≥ 65 years died within 30
37 days, with no deaths in those aged 18–64 years. Cardiovascular events occurred in 11.1% of
38 patients aged 18–64 and 36.4% of those aged ≥ 65 years.

39 **Conclusions:** Older adults in Germany face a high burden of RSV-related ARI hospitalizations,
40 including CAP, underscoring RSV vaccination's potential utility for this population.

41

42 **Key words:** Community-acquired pneumonia; Respiratory syncytial virus; Acute respiratory
43 infection hospitalization

44

45 **Conflicts of interests**

46 This study was funded by Pfizer Inc. Caihua Liang, Elizabeth Begier, Liz Wang, Claudia

47 Schwarz, Lea J. Bayer, Christof von Eiff, Qing Liu, Jo Southern, Jeffrey Vietri, Sonal Uppal,

48 Bradford D. Gessner, Christian Theilacker are Pfizer employees and may own Pfizer stock.

49 Stefan Hagel and Mathias Pletz received speaker honoraria and research funding from Pfizer.

50

51 **Funding**

52 This study was funded by Pfizer Inc.

53 **KEY PUBLIC HEALTH MESSAGE**

54 **What did you want to address in this study and why?**

55 Hospital administrative data significantly underestimate respiratory syncytial virus (RSV)
56 incidence due to infrequent testing and lower sensitivity of single nasopharyngeal/nasal swab
57 testing among adults. No prospective incidence studies are available for Germany and most
58 other European countries. We aimed to estimate RSV-related acute respiratory infection (ARI)
59 hospitalization incidence from a prospective community-acquired pneumonia (CAP) study and
60 adjust for undiagnosed RSV infections due to limited testing and use of nasopharyngeal/nasal
61 swab testing only. Detailed data on RSV disease burden are crucial for developing vaccination
62 policies.

63 **What have we learnt from this study?**

64 Adjusted annual incidence of RSV-related ARI rates were 18.4 (95% CI 11.0–28.9) and 377.6
65 (95% CI 340.5–417.7) per 100,000 population for adults 18–59 and ≥60 years, respectively.
66 Among RSV-positive CAP hospitalizations, 12.1% of patients aged ≥65 years died
67 within 30 days, with no deaths in those aged 18–64 years. Cardiovascular events
68 occurred in 11.1% of patients aged 18–64 and 36.4% of those aged ≥65 years.

69 **What are the implications of your findings for public health?**

70 Our findings are similar to recent time-series incidence results from Germany (236–363/100,000
71 for adults ≥60 years) and underscore the substantial burden of RSV among adults, particularly
72 the high rate of cardiovascular events contributes to a probably underestimated burden of RSV
73 disease.

74 **Introduction**

75 Lower respiratory tract infections (LRTIs) are leading causes of morbidity and mortality globally
76 [1, 2]. Pneumonia is the most common diagnosis of hospitalized acute lower respiratory tract
77 disease (aLRTD), accounting for 31% of aLRTD in a UK study [3] and 29% in a US prospective
78 cohort study [4]. In Germany, a recent retrospective cohort study using a representative
79 healthcare claims database reported an incidence of hospitalized community-acquired
80 pneumonia (CAP) 1,061 per 100,000 person-years in adults aged ≥ 60 years [5].

81
82 Respiratory syncytial virus (RSV) is now being recognized as one of the leading causes of acute
83 respiratory infections (ARIs) in older adults, including among patients with pneumonia [6, 7]. A
84 recent global systematic literature review and meta-analysis reported a pooled adjusted RSV-
85 related ARI hospitalization incidence of 347 per 100,000 for adults aged ≥ 65 years,
86 corresponding to 787,000 annual hospitalizations among older adults in high-income countries
87 [8]. In the US, roughly 2–9% of older adult pneumonia hospitalizations have been attributed to
88 RSV [6, 9] and this fraction increases to up to 15% during the winter months depending on the
89 diagnostic approaches used and the season under investigation [4, 10, 11]. RSV-related ARI
90 hospitalizations include pneumonia, but also non-pneumonic LRTI and exacerbations of
91 cardiopulmonary disease caused by RSV infection. In one study in Finland, pneumonia
92 accounted for 14% (3/22) of RSV-related ARI hospitalizations [4]. A more recent prospective
93 study using multiple specimen types found pneumonia to comprise 28% (71/254) of RSV-
94 related ARI hospitalizations when multiple additional specimen types (i.e., sputum, saliva and
95 blood) were added rather than relying on nasopharyngeal (NP)/nasal swab alone [12].

96
97 Accurate estimation of RSV-related hospitalization incidence is challenging due to several
98 causes of RSV case underascertainment [13]. RSV clinical presentation is non-specific and thus
99 diagnostic testing is necessary for confirmation of infection [10]; however this is infrequently

100 performed because it usually does not impact clinical management [13, 14]. When performed,
101 RSV laboratory testing may miss 50% of infections if only a single specimen is used for
102 diagnostic testing (often NP/nasal swab reverse transcription polymerase chain reaction [RT-
103 PCR]) [15, 16]. This is likely due to viral titers in respiratory secretions in adults being typically
104 lower than titers in children, so that RSV may no longer be detectable at the time of testing at
105 presentation/hospital admission [17], which tends to occur later in illness than for other
106 respiratory viruses [13].

107
108 Current assessments of RSV burden focus on RSV-related ARI hospitalizations, conducted
109 either through prospective studies utilizing direct diagnostic testing, retrospective studies using
110 diagnosis codes from large administrative databases, or through time-series modeling
111 approaches. Due to the reduced sensitivity of a single RT-PCR NP/nasal swab, prospective
112 estimates should be adjusted by the percentage increase in RSV detections associated with
113 using multiple diagnostic specimen types [8, 18]. Estimates based on diagnosis/ICD codes only
114 have been shown to substantially underestimate the RSV incidence globally and in Germany
115 [18-20]. Model-based studies link the variations in a broad definition of respiratory disease (e.g.
116 all respiratory diseases) to the variation in RSV activity to estimate the proportion of respiratory
117 disease attributable to RSV. This non-specific outcome definition can account for the
118 undiagnosed RSV cases, which might have been coded as other diseases [20, 21]. However,
119 results can vary by different modeling approaches and viral activity proxies selected and
120 prospective incidence studies are considered the gold standard.

121
122 Currently, no RSV-related hospitalization estimates based on active surveillance and
123 prospective testing are available for Germany. We used data from a prospective study of CAP
124 incidence [22] to estimate RSV-related CAP and ARI hospitalization incidence, including

125 adjustment for undiagnosed RSV infections due to use of NP/nasal swab testing only and non-
126 CAP ARI events.

127

128 **Methods**

129 *Study design and study population*

130 The CAP incidence study is a population-based multi-hospital, prospective study to determine
131 the CAP hospitalization incidence rate among adults aged ≥ 18 years in Thuringia, Germany.
132 Active surveillance for CAP has been conducted at three hospitals: Jena University Hospital
133 (JUH); the SRH Wald-Klinikum Gera; and the SRH Zentralklinikum Suhl. Study period for this
134 analysis is July 2021–June 2023 (24 months), encompassing two winter seasons. Adults who
135 met the following inclusion criteria were offered enrollment: aged ≥ 18 years at the time of
136 hospital admission with CAP and had evidence of pneumonia within first 48 hours of hospital
137 admission based on radiologic findings consistent with pneumonia and presence of ≥ 2 of
138 following 10 clinical signs or symptoms (fever within 24 hours before enrollment; hypothermia
139 within 24 hours of enrollment; chills or rigors; pleuritic chest pain; new or worsening cough;
140 sputum production; dyspnea; tachypnea; malaise; abnormal auscultatory findings suggestive of
141 pneumonia). Patients with radiologically-confirmed CAP were included in the analysis. The
142 number of unenrolled persons meeting inclusion/exclusion criteria was recorded to allow for
143 enumeration of all CAP hospitalizations regardless of enrollment status.

144

145 *Data sources*

146 NP/nasal swabs (or alternatively mid-turbinate nasal swabs) were collected from enrolled
147 participants and tested by multiplex nuclear acid amplification test (NAAT) for the presence of
148 respiratory viruses, including RSV.

149 The following data were collected from the study participants and hospital records on admission:
150 age, gender, study period, smoking status, alcohol use and chronic medical conditions. The risk
151 level was classified as low risk, at-risk and high-risk using CDC definitions for pneumococcal
152 disease [23], which are similar to risk factors for severe RSV infection [24, 25]. Cardiovascular
153 events were defined as any of the following: new or worsening heart failure, new or worsening
154 arrhythmia, acute coronary syndrome, cerebrovascular accident, deep venous thrombosis or
155 pulmonary embolism, or cardiovascular-related death.

156

157 *Definition of Catchment Area Population*

158 To estimate the RSV-related CAP incidence, the catchment area population was defined based
159 on residential zip codes. As uninterrupted CAP surveillance with full case capture was only
160 available from JUH, incidence estimations are based on this study site only. The total population
161 of adults aged ≥ 18 years from catchment area zip codes formed the denominator of the
162 incidence calculation. The observed unadjusted incidence rates were multiplied by the inverse
163 of the hospital market share in the catchment area (i.e., 97%) to adjust for healthcare seeking at
164 other facilities by residents of the catchment area.

165

166 *Statistical analysis*

167 Demographics and risk status were descriptively summarized for all patients meeting the case-
168 definition for CAP, according to testing status (tested and untested) and regardless of their
169 enrollment status. All variables were classified as either binary or categorical and are presented
170 as counts with percentages. The RSV positive proportion from NP/nasal swab alone
171 (unadjusted) was calculated as the number of RSV positive cases divided by the total number of
172 participants who had a valid NP/nasal swab test result. In order to adjust for underascertainment
173 of RSV detection based on use of NP/nasal swab testing alone, we used results from the

174 previously published prospective study detecting RSV using multispecimen types (referred to as
175 multispecimen study hereafter) [12]. The percent increase in RSV detection rate associated with
176 additional specimens was calculated using the positive proportion from NP/nasal swab plus
177 other specimens (i.e., saliva, paired serology, and sputum) and the positive proportion from
178 NP/nasal swab alone. This percent increase among different age groups served to correct for
179 underascertainment of RSV cases due to missed RSV infections associated with
180 nasopharyngeal/nasal swab diagnostic testing only.

181
182 The unadjusted RSV-related CAP incidence rates were calculated by multiplying age-group
183 specific proportions of RSV detection among tested patients with all-cause CAP incidence for all
184 eligible participants enrolled at Jena site, based on the assumption that RSV detection rate
185 would not differ significantly between those tested and untested. The adjusted RSV-related CAP
186 incidence rates were calculated using the percent increase in RSV detection obtained from the
187 multi-specimen study [12]. This was achieved by multiplying percent increase associated with
188 using multiple diagnostic testing specimens with the unadjusted RSV-related CAP incidence.
189 Incidence rate of RSV-related ARI hospitalizations (both unadjusted and adjusted) was then
190 estimated by dividing the RSV-related CAP incidence rates (unadjusted and adjusted) by the
191 proportions of CAP among RSV-associated ARI hospitalizations by age group, obtained from
192 the multi-specimen study [12]. The corresponding 95% confidence intervals (CIs) were
193 calculated by the exact method using Poisson distribution. R version 4.3.0 and SAS version 9.4
194 (SAS 9.4, Cary, NC. SAS Institute Inc.) were used to perform all analyses.

195

196 *Ethics/Ethical Approval*

197 All study participants or legal representatives were informed about the study and consented to
198 the participation. Local ethics committees approved the conduct of the study (2020-1947-
199 material).

200

201 **Results**

202 At JUH, there were 293 patients hospitalized with CAP tested for RSV by NP/nasal swab and
203 741 were not tested (including enrolled and non-enrolled patients). Patients not tested were
204 slightly older (84.2% aged ≥ 65 years vs 77.5%), had lower prevalence of high-risk conditions
205 (38.7% vs 58.4%) but a higher prevalence of at-risk conditions (52.8% vs 35.5%) than tested
206 individuals (Table 1).

207

208 *RSV detection among CAP patients*

209 Among 1,040 radiologically confirmed CAP cases enrolled and tested at the three study sites
210 between 01 July 2021 and 30 June 2023, 38 CAP cases had RSV detected, with an overall
211 positive proportion of 3.7% among adults aged ≥ 18 years (Supplementary Table S1). RSV
212 positive proportions were higher in the older age group (4.1% vs 2.4% for adults aged ≥ 60 years
213 and 18–59 years, respectively) and were generally higher in Year 2 (01. July 2022–30. June
214 2023) (5.5%) than Year 1 (01. July 2021–30. June 2022) (2.3%), however, they were similar
215 across risk status (3.3% for low-risk, 3.5% for at-risk and 3.9% for high-risk). After adjustment
216 for underascertainment of RSV cases, the overall positive proportion increased from 3.7% to
217 7.8%, corresponding to a 112% increase in RSV detection resulting from adding multiple
218 specimen results (i.e., saliva, paired serology, and sputum) beyond NP/nasal swab (Table 2).

219

220 *Incidence of RSV-related CAP and ARI hospitalization*

221 The unadjusted RSV-related CAP hospitalization rates were 1.9 (95% CI 0.2, 7.1) per 100,000
222 population in adults aged 18-59 years and 54.3 (95% CI 40.8, 70.8) per 100,000 population in
223 adults aged ≥ 60 years, respectively. Using the age-group specific percent increase in detection
224 associated with testing with additional specimen types (i.e., saliva, paired serology, and sputum)
225 as compared to NP/nasal swab alone from the multispecimen study [12] (Supplemental Table

226 S2), the adjusted incidence rate of RSV-related CAP hospitalizations was 4.7 (95% CI 1.5, 11.2)
227 per 100,000 population for adults aged 18–59 years and 109.1 (95% CI 89.6, 131.6) per
228 100,000 population for those aged ≥ 60 years. After applying the proportions of CAP among the
229 RSV-related ARI hospitalizations across different age groups [12], the estimated incidence rates
230 of RSV-related ARI hospitalizations (adjusted) were 18.4 (95% CI 11.0, 28.9) per 100,000
231 population for adults aged 18–59 years, and 377.6 (95% CI 340.5, 417.7) per 100,000
232 population for adults aged ≥ 60 years (Table 2). Incidence estimates in Year 2 were about 3
233 times higher than in Year 1.

234

235 *RSV-related CAP hospitalization outcomes*

236 Among RSV-positive CAP hospitalizations, 12.1% of patients aged ≥ 65 years died within 30
237 days of hospitalization; no deaths were observed for those aged 18–64 years among the 9
238 RSV-related CAP hospitalizations. Cardiovascular events (i.e., heart failure, arrhythmia, acute
239 coronary syndrome, cerebrovascular accident, deep venous thrombosis or pulmonary
240 embolism, and cardiovascular-related death) occurred in 11.1% and 36.4% of RSV-positive
241 patients 18–64 and ≥ 65 years of age within 30 days of CAP hospitalization.

242

243 **Discussion**

244 This analysis estimated the incidence rate of RSV-related ARI hospitalizations among adults
245 between 2021 to 2023 using the RSV incidence derived from an active surveillance CAP study
246 in Thuringia, Germany. The RSV positive proportion from NP/nasal swabs alone was 3.7% and
247 increased to 7.8% when adjusted for undiagnosed infections due to use of a single NP/nasal
248 swab compared to sampling with multiple diagnostic specimens (i.e., saliva, sputum, paired
249 acute/convalescent serology, and NP/nasal swab). With further adjustment for RSV-related
250 clinical presentations beyond CAP (e.g., non-pneumonic LRTI as well as chronic obstructive
251 pulmonary disease [COPD] and congestive heart failure [CHF] exacerbations), the adjusted

252 incidence rates of RSV-related ARI hospitalization for persons aged 18–59 years and ≥ 60 years
253 were 18 and 378 per 100,000 population, respectively. Finally, RSV-related CAP was
254 associated with a high risk for cardiovascular events within the month following CAP onset.

255
256 Results of our study are closely comparable to other RSV-related ARI hospitalization incidence
257 rates in the literature. First, these values were similar to a recent time-series model-based study
258 in Germany [21] (19–30, 33–51 and 236–363 cases per 100,000 person-years in adults aged
259 18-44, 45-59 and ≥ 60 years, respectively). Our estimates also aligned with incidence rates
260 reported in two systematic literature reviews with meta-analyses that included adjustment for
261 undiagnosed infections due to sole use of NP/nasal swab testing: one global meta-analysis of
262 prospective studies in high-income countries [8] (70 and 347 cases per 100,000 population in
263 adults aged 18-64 years and ≥ 65 years, respectively), and a US meta-analysis (19, 100, and
264 282 cases per 100,000 population in adults aged 18-49, 50–64, and ≥ 65 years, respectively)
265 [18].

266
267 We adjusted for undiagnosed RSV infections due to RSV detection relying on single NP/nasal
268 swab testing. Most RSV disease incidence studies in adults solely use RT-PCR of a NP/nasal
269 swab for RSV detection [8, 18], but multiple studies document that single specimen testing
270 misses RSV infections, and that adding an additional specimen such as sputum and paired
271 serology increases detection approximately 50% [16]. The multispecimen study documented
272 that adding multiple rather than a single specimen to NP/nasal swab approximately doubled
273 RSV detection [12, 15]. Adjustment of adult RSV disease incidence estimates for diagnostic
274 testing sensitivity has been incorporated in multiple recent studies, including meta-analyses of
275 RSV disease rates in high-income countries [8] and the United States [18] as well as in recent
276 US CDC incidence analyses [26]. Notably, the latter two studies only accounted for the
277 percentage increase in detection rate with adding one more specimen (1.3 to 1.5-fold) whereas

278 the most recent global study, similar to ours, included adjustment factors of ~2 to account for
279 the additional infections that would be identified through the synergistic effect of adding multiple
280 additional specimens (i.e., saliva, sputum, and paired serology).

281
282 In our study, more than one third of patients aged 65 years or older with RSV-related CAP
283 developed a cardiovascular event. Our results confirm previous observations of a high risk for
284 cardiovascular events following RSV infections in older adults consistent with more extensively
285 studied respiratory infections such as influenza and SARS-CoV-2 [27-29]. Time-series
286 modelling has also documented a linkage between RSV and acute cardiac events [30]. A recent
287 time-series study of hospitalization incidence in Germany found that 2–3% of cardiovascular
288 hospitalizations could be attributed to RSV infection [21].

289
290 Our study had several strengths. Broad screening criteria allowed for near complete case
291 capture and collection of minimal data on non-enrolled patients with study-qualifying CAP
292 allowed for accurate incidence estimations. Among enrolled patients, testing rates were high
293 (93%). A further strength of our study is the precise definition and consistent use of the
294 catchment area population based on residential zip codes, which allowed for accurate
295 estimations of RSV-related CAP incidence among adults.

296
297 The study also has several limitations. First, the estimation of RSV-related ARI hospitalization
298 incidence relies on the proportions of CAP among RSV-related ARI hospitalizations among
299 adults aged ≥ 40 years in the multispecimen study conducted in North America and may not be
300 fully applicable to the German population [12]. Available literature suggests that the estimate
301 that CAP is 28% of RSV-related ARI hospitalization [12] is conservative, as other publications
302 have reported percentages as low as 14% [4], which would have resulted in higher incidence
303 estimates. Second, diagnostic testing sensitivity adjustment in the current study was based on

304 results from a North American population 40 years and older. However, a recent systematic
305 literature found multiple studies documenting the reduced sensitivity of single NP/nasal swab
306 PCR testing and similar results were seen among different adult age groups and geographical
307 settings [16]. Further, minimal differences by age in the underascertainment of single specimen
308 were seen within the study itself and this is the largest study of its kind with 3,669 participants
309 tested and 2 countries represented (US and Canada) [12]. Third, we assumed that CAP
310 participants who received RSV testing would have the same RSV detection rate as those who
311 were not tested. Untested persons, especially those that could not be enrolled in the study
312 because of lack of informed consent may have had a different detection rate since they tended
313 to be slightly older but were less likely to be at high-risk. However, the RSV detection rates were
314 observed to be similar across risk status (3.3% for low-risk, 3.5% for at-risk and 3.9% for high-
315 risk). Fourth, incidence rates were calculated for Jena only and the city's catchment population
316 is somewhat younger than the national average, potentially leading to lower RSV incidence than
317 would have been seen in Germany as a whole as RSV-related hospitalization incidence is known
318 to increase with age [18,19]. Lastly, the surveillance period in the CAP incidence study
319 coincided with the COVID-19 pandemic and its immediate aftermath with larger fluctuations of
320 incidence, which may not reflect future RSV incidence.

321
322 While RSV burden estimates relying on standard-of care testing or hospital discharge codes
323 result in a large underestimation of the RSV-related ARI incidence, our study based on
324 prospective, active population-based surveillance and adjustment for underascertainment
325 provides more accurate and complete estimates. The high risk of case-fatality and
326 cardiovascular events after RSV-related CAP confirms similar observations from other studies
327 with larger sample size. The study results underscore the substantial burden of RSV among
328 adults in Germany. This evidence is essential for the evaluation and implementation of novel
329 antiviral agents for treatment and vaccines for prevention of infections due to RSV.

330 **Acknowledgements**

331 Steffi Kolanos led the study nurse team and were responsible for the local logistics of the study.

332 Susana Cubillos de Schmeer took over the management of the study team in the final phase of

333 the study. The study nurses Stephanie Beier, Jana Schmidt, Janine Wittig and Claudia Merbold

334 enrolled the patients.

335

336 **Data availability**

337 All data generated or analyzed during this study are included in this published article and

338 supplementary materials.

339

340 **Ethical statement**

341 All study participants or legal representatives were informed about the study and consented to

342 the participation. The study was approved by the Ethics Committee of the Jena University

343 Hospital on 19 November 2020 (reg.no. "2020-1947- material") and also by the

344 Landesärztekammer Thüringen (local ethics committee) on 22 December 2020.

345

346 **Authors' contributions**

347 C.L., E.B., B.D.G., C.T., and M.P. contributed to conception and/or study design. C.L., E.B.,

348 S.H., L.W., Q. L., C.T., and M.P. were involved in acquisition of data, analysis and interpretation

349 of data. C.L., E.B., S.H., J.A., L.W., C.S., L.J.B., C.V.E., Q.L., J.S., J.V., S.U., B.D.G., C.T., and

350 M.P. participated in drafting or revision of the submitted article.

351 References

- 352 1. Feldman C, Shaddock E. Epidemiology of lower respiratory tract infections in adults. *Expert Rev*
353 *Respir Med*. 2019;13(1):63-77.
- 354 2. Collaborators GBDLRI. Estimates of the global, regional, and national morbidity, mortality, and
355 aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the
356 Global Burden of Disease Study 2016. *Lancet Infect Dis*. 2018;18(11):1191-210.
- 357 3. Hyams C, Begier E, Garcia Gonzalez M, Southern J, Campling J, Gray S, et al. Incidence of acute
358 lower respiratory tract disease hospitalisations, including pneumonia, among adults in Bristol, UK, 2019,
359 estimated using both a prospective and retrospective methodology. *BMJ Open*. 2022;12(6):e057464.
- 360 4. Aronen M, Viikari L, Kohonen I, Vuorinen T, Hameenaho M, Wuorela M, et al. Respiratory tract
361 virus infections in the elderly with pneumonia. *BMC Geriatr*. 2019;19(1):111.
- 362 5. Theilacker C, Sprenger R, Leverkus F, Walker J, Hackl D, von Eiff C, et al. Population-based
363 incidence and mortality of community-acquired pneumonia in Germany. *PLoS One*.
364 2021;16(6):e0253118.
- 365 6. Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an
366 assessment of disease burden. *J Infect Dis*. 1999;179(1):25-30.
- 367 7. van Asten L, van den Wijngaard C, van Pelt W, van de Kasstele J, Meijer A, van der Hoek W, et
368 al. Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial
369 virus, influenza B, norovirus, and parainfluenza in elderly persons. *J Infect Dis*. 2012;206(5):628-39.
- 370 8. Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, et al. Adjusting for Case Under-
371 Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a
372 Systematic Review and Modelling Study. *Infect Dis Ther*. 2023;12(4):1137-49.
- 373 9. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-Acquired
374 Pneumonia Requiring Hospitalization among U.S. Adults. *N Engl J Med*. 2015;373(5):415-27.
- 375 10. Falsey AR. Respiratory syncytial virus infection in adults. *Semin Respir Crit Care Med*.
376 2007;28(2):171-81.
- 377 11. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. *Clin Microbiol Rev*.
378 2000;13(3):371-84.
- 379 12. Aliabadi N, Ramirez J, McGeer A, Liu Q, Carrico R, Mubareka S, et al., editors. Detection of
380 Respiratory Syncytial Virus (RSV) using nasopharyngeal specimens (NPS) alone significantly
381 underestimates disease incidence in adults hospitalized with acute respiratory infections (ARI): an
382 updated, pooled analysis from North America. Poster presentation. 8th Global ReSViNET Conference on
383 Novel RSV Preventive and Therapeutic Interventions; 2024 February 13-16, 2024 Mumbai, India.
- 384 13. Rozenbaum MH, Begier E, Kurosky SK, Whelan J, Bem D, Pouwels KB, et al. Incidence of
385 Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data. *Infect Dis Ther*.
386 2023;12(6):1487-504.
- 387 14. Rozenbaum MH, Judy J, Tran D, Yacisin K, Kurosky SK, Begier E. Low Levels of RSV Testing Among
388 Adults Hospitalized for Lower Respiratory Tract Infection in the United States. *Infect Dis Ther*.
389 2023;12(2):677-85.
- 390 15. Ramirez J, Carrico R, Wilde A, Junkins A, Furmanek S, Chandler T, et al. Diagnosis of Respiratory
391 Syncytial Virus in Adults Substantially Increases When Adding Sputum, Saliva, and Serology Testing to
392 Nasopharyngeal Swab RT-PCR. *Infect Dis Ther*. 2023;12(6):1593-603.
- 393 16. Onwuchekwa C, Moreo LM, Menon S, Machado B, Curcio D, Kalina W, et al. Underascertainment
394 of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic
395 Literature Review and Meta-analysis. *J Infect Dis*. 2023;228(2):173-84.
- 396 17. Walsh EE, Falsey AR. Respiratory syncytial virus infection in adult populations. *Infect Disord Drug*
397 *Targets*. 2012;12(2):98-102.

- 398 18. McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of Medically Attended
399 RSV Among US Adults: A Systematic Review and Meta-analysis. *Open Forum Infect Dis.*
400 2022;9(7):ofac300.
- 401 19. Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, et al. Evaluation of using ICD-10 code
402 data for respiratory syncytial virus surveillance. *Influenza Other Respir Viruses.* 2020;14(6):630-7.
- 403 20. Haeberer M, Bruyndonckx R, Polkowska-Kramek A, Torres A, Liang C, Nuttens C, et al. Estimated
404 Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain,
405 2016-2019. *Infect Dis Ther.* 2024;13(3):463-80.
- 406 21. Polkowska-Kramek A, Begier E, Bruyndonckx R, Liang C, Beese C, Brestrich G, et al. Estimated
407 Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among
408 Adults in Germany Between 2015 and 2019. *Infect Dis Ther.* 2024.
- 409 22. Ankert J, Hagel S, Schwarz C, Pan K, Wang L, von Eiff C, et al. *Streptococcus pneumoniae* re-
410 emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-
411 2, in Germany, 2021. *ERJ Open Res.* 2023;9(3).
- 412 23. CDC. Risk Factors for Pneumococcal Disease [Available from:
413 [https://www.cdc.gov/pneumococcal/about/risk-
414 transmission.html#:~:text=Conditions%20and%20other%20factors%20that,kidney%2C%20liver%2C%20
415 or%20lung%20disease.](https://www.cdc.gov/pneumococcal/about/risk-transmission.html#:~:text=Conditions%20and%20other%20factors%20that,kidney%2C%20liver%2C%20or%20lung%20disease.)
- 416 24. Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of Respiratory Syncytial
417 Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices
418 - United States, 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(29):793-801.
- 419 25. Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, et al. Systematic Literature Review
420 of Risk Factors for Poor Outcomes Among Adults With Respiratory Syncytial Virus Infection in High-
421 Income Countries. *Open Forum Infect Dis.* 2023;10(11):ofad513.
- 422 26. Havers FP, Whitaker M, Pham H, Anglin O, Milucky J, Patel K, et al. 2209. RSV-associated
423 Hospitalizations in Adults Aged ≥ 18 Years and the Impact of the COVID-19 Pandemic in the United
424 States, October 2018 – February 2022. *Open Forum Infect Dis.* 2022;9(Suppl 2): ofac492.1828.
- 425 27. Woodruff RC, Melgar M, Pham H, Sperling LS, Loustalot F, Kirley PD, et al. Acute Cardiac Events
426 in Hospitalized Older Adults With Respiratory Syncytial Virus Infection. *JAMA Intern Med.* 2024.
- 427 28. Ubamadu E BE, Gessner BD et al. Respiratory syncytial virus sequelae among adults in high-
428 income countries. A systematic literature review and meta-analysis. *Infect Dis Ther.* May 2024 In Press.
- 429 29. Ivey KS, Edwards KM, Talbot HK. Respiratory Syncytial Virus and Associations With
430 Cardiovascular Disease in Adults. *J Am Coll Cardiol.* 2018;71(14):1574-83.
- 431 30. Bruyndonckx R, Polkowska-Kramek A, Liang C, Nuttens C, Tran TMP, Gessner BD, et al.
432 Estimation of Symptomatic Respiratory Syncytial Virus Infection Incidence in Adults in Multiple
433 Countries: A Time-Series Model-Based Analysis Protocol. *Infect Dis Ther.* 2024;13(4):953-63.
434

Tables

Table 1. Characteristics of adults hospitalized at Jena University Hospital with radiologically-confirmed CAP patients by RSV testing status

	NP/Nasal Swab Tested		NP/Nasal Swab Untested***		P-Value
	N	%	N	%	
Overall	293	100	741	100	
Age group					
18-59 years	38	13	73	9.9	0.145
≥60 years	255	87	668	90.1	0.145
18-64 years	66	22.5	117	15.8	0.010
≥65 years	227	77.5	624	84.2	0.010
Sex					
Female	125	42.7	309	41.7	0.778
Male	168	57.3	432	58.3	
Study period*					
Year 1	135	46.1	341	46	0.987
Year 2	158	53.9	400	54	0.987
Overall study period	293	100	741	100	
Risk status**					
Low-risk	18	6.1	62	8.4	0.228
At-risk	104	35.5	391	52.8	<0.001
High-risk	171	58.4	287	38.7	<0.001

Abbreviations: CAP=community-acquired pneumonia; CDC = centers for disease. NP/nasal swab=nasopharyngeal (NP)/nasal swab

* Year 1: 01Jul2021 – 30Jun2022; Year 2: 01Jul2022 – 30Jun2023

** The risk status was classified using CDC definitions for pneumococcal disease [23]

*** include enrolled and non-enrolled patients

Table 2 Unadjusted and adjusted incidence rates of RSV-related CAP and ARI hospitalizations in Thuringia/Germany 2021–2023

Age group (Years)	CAP incidence rate (per 100, 000) ¹	RSV positive proportion based on NP/nasal swab ¹	Percentage Increase in RSV detection ²	RSV-related CAP incidence rate per 100,000 (95% confidence interval) ³		Proportion of CAP in RSV-related ARI hospitalization ⁵	RSV-related ARI incidence rate per 100,000 (95% confidence interval) ⁶	
				Unadjusted	Adjusted ⁴		Unadjusted	Adjusted
Year 1: 01Jul2021 – 30Jun2022								
≥18	451.0 (410.0, 494.5)	2.3%	112%	10.4 (5.1,18.9)	22.0 (13.8, 33.3)	28.0%	37.0 (26.1, 51.0)	78.5 (62.1, 97.9)
18-59	87.7 (70.6, 108.4)	2.3%	148%	2.0 (0.2,7.2)	5.0 (1.6, 11.7)	25.4%	7.9 (3.4, 15.6)	19.7 (12.0, 30.5)
≥60	1188.0 (1121.8, 1257.1)	2.3%	101%	27.3 (18.0,39.6)	54.9 (41.3, 71.5)	28.9%	94.5 (76.4, 115.6)	190.0 (163.9, 219.0)
18-64	119.4 (98.6, 142.4)	1.7%	141%	2.0 (0.2, 7.2)	4.9 (1.6, 11.5)	22.6%	9.0 (4.1, 17.1)	21.6 (13.5, 32.8)
≥65	1384.5 (1312.5, 1458.3)	2.7%	95%	37.4 (26.4, 51.5)	72.9 (57.1, 91.7)	31.8%	117.6 (97.3, 140.9)	229.2 (200.5, 260.9)
Year 2: 01Jul2022 – 30Jun2023								
≥18	528.7 (485.0, 575.9)	5.5%	112%	29.1 (19.5, 41.8)	61.6 (47.2, 79.0)	28.0%	103.9 (84.9, 125.9)	220.2 (192.1, 251.3)
18-59	69.3 (53.7, 87.3)	2.6%	148%	1.8 (0.2, 6.9)	4.5 (1.4, 11.0)	25.4%	7.1 (2.9, 14.6)	17.6 (10.4, 28.0)
≥60	1460.6 (1387.5, 1537.3)	6.1%	101%	89.1 (71.6, 109.6)	179.1 (153.8, 207.3)	28.9%	308.3 (274.8, 344.7)	619.7 (571.9, 670.5)
18-64	115.6 (95.9, 139.1)	4.2%	141%	4.9 (1.6, 11.5)	11.7 (6.0, 20.6)	22.6%	21.5 (13.4, 32.7)	51.8 (38.7, 68.0)
≥65	1691.7 (1613.0, 1773.9)	6.0%	95%	101.5 (82.7, 123.3)	197.9 (171.3, 227.5)	31.8%	319.2 (285.1, 356.2)	622.4 (574.5, 673.3)
Overall study period: 01Jul2021 – 30Jun2023								
≥18	489.8 (460.4, 520.6)	3.7%	112%	18.1 (10.7, 28.6)	38.4 (27.2, 52.6)	28.0%	64.7 (49.9, 82.5)	137.2 (115.2, 162.2)
18-59	78.5 (64.6, 94.5)	2.4%	148%	1.9 (0.2, 7.1)	4.7 (1.5, 11.2)	25.4%	7.4 (3.1, 15.0)	18.4 (11.0, 28.9)
≥60	1324.3 (1241.3, 1411.3)	4.1%	101%	54.3 (40.8, 70.8)	109.1 (89.6, 131.6)	28.9%	187.9 (162.0, 216.8)	377.6 (340.5, 417.7)
18-64	117.5 (101.1, 135.8)	2.5%	141%	2.9 (0.6, 8.6)	7.1 (2.9, 14.6)	22.6%	13.0 (6.9, 22.2)	31.3 (21.3, 44.4)
≥65	1538.1 (1437.9, 1643.2)	4.2%	95%	64.6 (49.8, 82.4)	126.0 (105.0, 150.0)	31.8%	203.1 (176.1, 233.0)	396.1 (358.0, 437.1)

Abbreviations: CAP=community-acquired pneumonia; ARI= acute respiratory infection; RSV=respiratory syncytial virus; NP/nasal swab=nasopharyngeal (NP)/nasal swab1. Obtained from the active, population-based surveillance study. CAP incidence estimates are taking into account Jena patients only; however, all three sites contributed to the RSV positive proportion

2. Percentage increase with additional specimen type results beyond NP/nasal swab, obtained from the multi-specimen study*

3. Assumes the RSV positive proportion is the same among CAP patients tested and untested.

4. Adjusted for the underascertainment of RSV detection using the percentage increase with additional specimen type results beyond NP/nasal swab, obtained from the multi-specimen study*

5. Proportions of CAP among RSV-related ARI hospitalizations were obtained from the multi-specimen study*

6. Calculated by dividing RSV-related CAP incidence by the proportion of CAP in RSV-related ARI hospitalizations

* Aliabadi N, et al Detection of Respiratory Syncytial Virus (RSV) using nasopharyngeal specimens (NPS) alone significantly underestimates disease incidence in adults hospitalized with acute respiratory infections (ARI): an updated, pooled analysis from North America. 8th Global ReSViNET Conference. Mumbai, India2024.